Products
As of June 2020
| Brand Name | Launch | Indications | Licensor | |
|---|---|---|---|---|
| 1 | NOBELZIN® | Apr 2008 | Wilson’s disease | Teva |
| 2 | LUNABELL® LD | Jul 2008 | dysmenorrhea | Janssen |
| 3 | NOBELBAR® | Dec 2008 | neonatal seizures, status epilepticus |
in-house/ Kagawa Univ |
| 4 | Fostoin® | Jan 2012 | status epilepticus, prevention of postoperative seizures, etc. |
Pfizer |
| 5 | GLIADEL® | Jan 2013 | malignant glioma | Eisai |
| 6 | INDACIN® | Jan 2013 | patent ductus arteriosus of prematurity | Lundbeck |
| 7 | COSMEGEN® | Jan 2013 | Wilms’ tumor, chorionepitelioma, pediatric solid malignant tumor, etc. |
Lundbeck |
| 8 | LUNABELL® ULD | Sep 2013 | dysmenorrhea | Janssen |
| 9 | Alabel® | Sep 2013 | diagnosis of malignant glioma | medac |
| 10 | Unitalc® | Dec 2013 | prevention of recurrent malignant pleural effusion | Novatech/ Nagoya Medical Center |
| 11 | Respia® | Dec 2014 | apnea of prematurity | Nippon Boehringer (co-development) |
| 12 | RAPALIMUS® | Dec 2014 | lymphangioleiomyomatosis | Pfizer/ Niigata Univ |
| 13 | ZANOSAR® | Feb 2015 | gastroenteropancreatic neuroendocrine tumor | Keocyt |
| 14 | NOBELZIN® | Mar 2017 | hypozincemia | In-house |
| 15 | RAPALIMUS® Gel | Jun 2018 | tuberous sclerosis-associated skin lesions | Osaka Univ/ In-house |
| 16 | TITANBRIDGE® (medical device) |
Jul 2018 | adductor spasmodic dysphonia | TRI (Translational Research Center for Medical Innovation)/ Kumamoto Univ |
| 17 | JEMINA® | Oct 2018 | dysmenorrhea | In-house |
| 18 | RETYMPA®250ΜG SET | Dec 2019 | tympanic perforation | TRI/ Kaken |
| 19 | Melatobel®granules 0.2% | Jun 2020 | Sleep-onset difficulty associated with neurodevelopmental disease in children | in-house |
- Research and Development